<DOC>
	<DOCNO>NCT01168349</DOCNO>
	<brief_summary>This observational study evaluate clinical benefit NeoRecormon ( epoetin beta ) daily routine practice cancer patient anemia . Data collect patient receive chemotherapy solid tumor hematological malignancy . Patients follow 28 week .</brief_summary>
	<brief_title>An Observational Study NeoRecormon ( Epoetin Beta ) Cancer Patients With Anemia ( FAST )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Patients receive myelosuppressive chemotherapy solid tumor , hematological malignancy autograft hematological malignancy Patients treatment epoetin beta start inclusion visit Life expectancy &gt; /=6 month accord physician Patients accept able complete French write questionnaire his/her professional social activity visit Patients receive erythropoiesisstimulating agent treatment , red blood cell transfusion within 4 week enrollment Participation clinical trial oncohematology Patients myelodysplasia Patients one active malignancy time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>